Boehringer Ingelheim merges AMAL and ViraTherapeutics cancer units, Dantari sells assets to Adanate, Madrona raises $770M, and Abdera adds JJDC and Foresite as investors.

A new report from Novotech reveals the OV market is expanding at pace, with a compounding annual growth rate of 14.2% between 2019 and 2024. More than 95% of ongoing trials involving oncolytic viruses ...

Replimune Group Inc (NASDAQ:REPL), a biotechnology company specializing in oncolytic immunotherapy for cancer treatment, ...

Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech and small to ...

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will participate in the ...

Scientists in China have developed a modified virus that causes cancer cells to make sugars normally found in pigs, causing ...

The confirmatory IGNYTE-3 trial is assessing RP1 in combination with nivolumab in patients with advanced melanoma who have progressed on anti-PD-1 and anti-CTLA-4 therapies or are ineligible for ...

As our knowledge of science and the human body expands, so too do doctors have more tools at hand when treating cancer. One ...

LOAd703, an oncolytic adenovirus with transgenes for 4-1BBL and TMZ-CD40L, has received FDA fast track designation for ...